This manuscript reports on a patient with a metastatic gastrointestinal stromal tumor (GIST) refractory to standard first-line treatment, who underwent a gallium-68 scan based on pre-clinical data of somatostatin receptor (SSTR) expression in such tumors. The gallium-68 DOTATATE scan determined significant somatostatin receptor avidity as hypothesized, suggesting that this imaging modality may ...

Aims and Objectives: Assessment of renal toxicity profile of 177Lu-DOTATATE based Peptide Receptor Radionuclide therapy (PRRT) in patients of Metastatic Neuroendocrine tumor (NET) with a single functioning kidney. Materials and Methods: This was a retrospective analysis of NET patients, who had undergone PRRT with 177Lu-DOTATATE at a large tertiary care centre. The patients selected for the stu...

Introduction: In Peptide Receptor Radionuclide Therapy (PRRT), the administration of radionuclide such as Lu-177 label with a pharmaceutical agent useful to destroy the lesion. The amount of Lu-177 radioactivity administered to the patients is still not standardize and generally not more than 7.4 GBq per session due to the patient’s safety issues. The first cycle of Lu-177 is a...